A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs.
Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or
Metastatic Renal Cell Carcinoma
This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma.